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Abstract
The expression of differentiation-associated surface antigens
by the clonogenic leukemic cells from 20 patients with acute
myeloblastic leukemia (AML) was studied with a panel of
seven cytotoxic monoclonal antibodies (anti-Ia, -MY9, -PM-
81, -AML-2-23, -Mol, -Mo2, and -MY3). The surface antigen
phenotypes of the clonogenic cells were compared with the
phenotypes of the whole leukemic cell population, and with
the phenotypes of normal hematopoietic progenitor cells. In
each case the clonogenic leukemic cells were found within a
distinct subpopulation that was less "differentiated" than the
total cell population. Clonogenic leukemic cells from different
patients could be divided into three phenotype groups. In the
first group (7 of 20 cases), the clonogenic cells expressed
surface antigens characteristic of the normal multipotent colony-
forming cell (Ia, MY9). These cases tended to have "undiffer-
entiated" (FAB Ml) morphology, and the total cell population
generally lacked expression of "late" monocyte antigens such
as MY3 and Mo2. A second group (seven cases) of clonogenic
cells expressed surface antigens characteristic of an "early"
(day 14) colony-forming unit granulocyte-monocyte (CFU-GM),
and a third group (six cases) was characteristic of a "late"
(day 7) CFU-GM. The cases in these latter two groups tended
to have myelomonocytic (FAB M4) morphology and to express
monocyte surface antigens. These results suggest that the
clonogenic cells are a distinct subpopulation in all cases of
AML, and may be derived from normal hematopoietic progenitor
cells at multiple points in the differentiation pathway. The
results further support the possibility that selected monoclonal
antibodies have the potential to purge leukemic clonogenic
cells from bone marrow in some AML patients without elimi-
nating critical normal progenitor cells.
Introduction
Acute myeloblastic leukemia (AML)' is a clonal malignant
disorder of myeloid progenitor cells that results in the progres-
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1. Abbreviations used in this paper: AMoL, acute monocytic leukemia;
AML, acute myeloblastic leukemia; AMML, acute myelomonocytic
leukemia; CFU-GM, colony-forming unit granulocyte-monocyte;
DMSO, dimethyl sulfoxide; IMDM, Iscove's modified Dulbecco's
sive accumulation of leukemic cells that fail to differentiate
normally (1). A small subset of leukemic cells from many
patients with AML has the ability to form a colony in vitro in
semisolid medium (2, 3). These clonogenic cells, leukemic
colony-forming cells (L-CFC), have several properties that are
not shared by the majority of leukemic cells: a high fraction
of L-CFC is in S-phase (4), the cells have the ability to divide
five or more times in vitro, and at least a subset of L-CFC has
self-renewal capability (5). L-CFC share these properties with
normal myeloid progenitor cells, and it has been suggested
that the L-CFC act in vivo as progenitor cells to maintain the
rest of the leukemic cell population (4, 6). However, despite
having properties of a progenitor cell, the relationships between
L-CFC and the total leukemic population have not been
defined.
We have previously demonstrated that differentiation-as-
sociated myeloid surface antigens detected by monoclonal
antibodies could be used to identify L-CFC as a distinct
subpopulation of cells in some patients with acute myelomon-
ocytic leukemia (AMML) (7). It was shown that L-CFC
expressed antigens characteristic of very immature cells (Ia,
MY7) but lacked MY4, an antigen characteristic of later
monocytic cells, despite the fact that a majority ofthe leukemic
cells in AMML patients express MY4. These preliminary
observations thus suggested that the highly proliferative MY4
negative L-CFC may indeed function as progenitor cells, giving
rise to MY4 positive cells that have minimal proliferative
potential, a situation analogous in some respects to normal
myelopoiesis.
In this study, we have investigated the surface antigens of
L-CFC in 20 patients with AML with the goals of (a) comparing
L-CFC with the majority of the leukemic cells in each patient;
(b) comparing L-CFC from different AML patients of different
morphologic subtypes, and (c) comparing L-CFC with normal
bone marrow colony-forming cells. The results demonstrate
that L-CFC are a distinct subpopulation of leukemic cells in
virtually all cases ofAML and can be distinguished from more
differentiated leukemic cells by their surface antigen phenotype.
Three different "stages" of L-CFC were defined by the pro-
gressive acquisition of surface antigens in a sequence analogous
to normal granulocyte-monocyte progenitor cell maturation.
Finally, the degree of in vivo differentiation of leukemic cells
in individual AML patients is at least partially dependent on
the stage of L-CFC present in that patient.
Methods
Monoclonal antibodies. Production and characterization of murine
monoclonal antibodies anti-MY3, anti-MY9, anti-AML-2-23, and
anti-PM-8 1 have been previously described (8-1 1). Anti-Mo I and anti-
medium; L-CFC, leukemic colony-forming cells; MEM, minimal es-
sential medium; CFU-Mix, colony-forming unit-mixed granulocyte/
erythrocyte; NSE, nonspecific esterase; SE, specific esterase.
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Mo2 antibodies (12) were provided by Dr. Robert Todd (Dana-Farber
Cancer Institute) and anti-12 (anti-Ia) (13) by Dr. Lee Nadler (Dana-
Farber Cancer Institute). Anti-PM-8 1, Mo 1, Mo2, and MY3 are of the
IgM subclass; anti-MY9 and anti-AML-2-23 are of the IgG2b subclass;
and anti-12 is of the IgG2a subclass. Anti-MY3 recognizes the same
antigen determinant (55,000 mol wt) recognized by anti-MY4 (which
is not lytic). All antibodies were lytic with rabbit complement at titers
of greater than 1:1,000 dilution of ascites.
Leukemic samples. Peripheral blood or bone marrow aspirate cells
were obtained under sterile conditions from untreated patients with
AML after they gave informed consent. Mononuclear cells were
prepared by Ficoll-Hypaque sedimentation (1.077 g/cm3). Leukemic
cells were cryopreserved in 10% dimethyl sulfoxide (DMSO) in the
vapor phase of liquid nitrogen and later thawed using DNAase (100
Ag/ml, Worthington Diagnostic Systems, Freehold, NJ) in minimal
essential medium with 2.5% human AB serum. Wright's stained
cytocentrifuge smears were examined to determine the percentage of
leukemic blasts. All patients had >54% blasts in the analyzed sample
and usually >75%.
The diagnosis of AML using FAB classification criteria (14) was
established by standard techniques using Wright-Giemsa stained smears,
alpha-naphthylacetate esterase (nonspecific esterase, NSE), and naphthol
AS-D cloroacetate esterase (specific esterase, SE) staining patterns. FAB
types Ml and M2 showed no monocytoid features and were generally
SE+ and NSE-. Acute myelomonocytic leukemias (AMML, FAB
type M4) showed morphological features of partial monocytic differ-
entiation and tended to be NSE+ and SE+. Acute monocytic leukemia
(AMoL, FAB type M5) tended to be NSE+ and SE-.
In some experiments, bone marrow cells were obtained from
normal volunteers and similarly processed. Studies on normal cells
were performed on fresh (noncryopreserved) samples.
Colony assays for normal and leukemic progenitor cells. L-CFC (7,
15, 16) and normal granulocyte-monocyte progenitor cells (CFU-GM)
(17) were assayed by plating 0.25-1.0 X 1O' cells/ml in 0.5 ml cultures
in Iscove's modified Dulbecco's medium (IMDM, Gibco Laboratories,
Grand Island, NY) containing 20% fetal calf serum (FCS, Flow
Laboratories, Inc., Rockville, MD), 10% GTC conditioned medium
(Gibco) (18), and 0.3% agar (Agar Noble, Difco Laboratories, Detroit,
MI) over an underlayer containing 0.5% agar in the same medium.
After 7-10 d, the agar overlayers were removed from the underlayers,
dried on glass slides, fixed in methanol, and stained for SE and NSE
activity and counter-stained with hematoxylin as previously described
(19). All patients' colonies stained positively for either SE or NSE, or
both. The cells in all colonies were morphologically blast cells, confirming
their leukemic origin. Colonies composed of normal appearing granu-
locytes were rarely observed in this study. This assay system did not
appear to support the growth of T cell colonies (7, 9). Aggregates of
greater than 20 blast cells were enumerated as leukemic colonies (4,
5). Normal bone marrow or peripheral blood CFU-GM were assayed
in the same manner. CFU-GM were enumerated on day 7 (clusters of
4-39 cells plus colonies of 40 or more cells) and day 14 (colonies of
40 or more cells). Mixed colonies (colony forming unit-mixed granu-
locyte/erythrocyte; CFU-Mix) were cultured in IMDM containing 0.9%
methycellulose, 30% FCS, 2 X 10-s M 2-mercaptoethanol (Sigma
Chemical Co., St. Louis, MO), and 10% phytohemagglutinin-stimulated
leukocyte conditioned medium (20). Erythropoietin (1 U/ml, Step III,
Connaught Laboratories, Swiftwater, PA) was added on day 4. Marrow
cells were plated at 1 x 105/ml and mixed lineage colonies counted
after 14-16 d.
Complement lysis. To determine the surface antigen phenotype of
the CF[J-Mix, CFU-GM, and L-CFC, aliquots of I X 106 cells suspended
in RPMI 1640 (Gibco Laboratories) with 10% FCS were incubated
with monoclonal antibodies (1:250 dilution of ascites) for 30 min at
4°C. After one wash step, the cells were suspended in rabbit complement
(3-4-wk-old rabbits, Pel-Freeze Biologicals, Rogers, AR) at a dilution
of 1:6. The complement had been previously adsorbed with fresh
normal bone marrow mononuclear cells and had no demonstrable
toxicity against CFU-GM or L-CFC. After 90 min at 370C the cells
were washed once and resuspended in IMDM containing 20% FCS for
colony assay. Negative controls included treatment with complement
alone, and treatment with a nonbinding IgG monoclonal antibody
(8A7) plus complement. Anti-beta-2-microglobulin (supplied by Dr.
L. Nadler, Dana Farber Cancer Institute) was used as a positive
control, and routinely produced lysis of >95% of L-CFC or CFU-GM.
Immunofluorescence assays. Antibody reactivity with the whole
leukemic cell population cells was determined by indirect immunoflu-
orescence (8). Aliquots of 0.5-1.0 X 106 cells were incubated (40C, 30
min) with 100 Al of antibody (ascites fluid diluted 1:250 in minimal
essential medium (MEM) containing 2.5% human AB serum, washed
two times, and further incubated with fluorescein-conjugated goat anti-
mouse Ig (Tago Laboratories, Burlingame, CA). After two additional
wash steps, fluorescent antibody-coated cells were detected by a flow
cytometer (FC200/4800A, Ortho Instruments, Westwood, MA). Back-
ground fluorescence, determined by using a nonreactive monoclonal
IgG antibody, was subtracted. For the experiments described in Table
IV, a positive reaction was considered to be >20% of cells more
fluorescent than background.
Results
AML patient population. Samples from 113 patients were
tested for in vitro colony formation according to the condition
described in Methods. The morphological subtypes of these
patients using the FAB classification were Ml, 24%; M2, 10%;
M3, 8%; M4, 44%; and M5, 14%. 53 patients (47%) displayed
no in vitro growth, 34 (30%) formed clusters of 3-19 cells,
and 26 (23%) formed colonies composed of more than 20
cells. Sufficient cells were available from 20 of these latter
cases for repeated testing, and an analysis of these samples
forms the basis of this report. The diagnosis of AML was
established in all cases by standard morphologic and cytochem-
ical criteria (14), and confirmed by surface marker analy-
sis (2 1).
Table I. Patient Characteristics
Patient FAB Sources* Percent
number Age Sex classification of cells blasts
1 65 M M4 BM 95
2 52 F M I PB 99
3 82 M M2 PB 54
4 29 M M I PB 90
5 24 F M I PB 90
6 1 M M I BM 80
7 33 M M5 PB 90
8 27 F M4 BM 85
9 37 M M4 BM 95
10 10 M M4 PB 99
11 67 F M4 PB 90
12 53 F M5 BM 90
13 NAt M M4 PB 75
14 2 F M4 BM 100
15 29 M M4 PB 90
16 4 F M4 PB 90
17 51 F M4 PB 85
18 NA F NA PB 95
19 83 F M4 PB 95
20 83 F M2 BM 90
* Bone marrow (BM) or peripheral blood (PB).
t Information not available.
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A summary of clinical characteristics of the patient popu-
lation is shown in Table I. The patients ranged in age from 1
to 83 yr (median, 43 yr). There were 9 males and 11 females.
20% of patients' cells were classified as FAB type Ml, 10% as
M2, 55% as M4, and 10% as M5. The cells of one patient
(number 18) were not classifiable by FAB criteria and are
listed as "unclassified." 65% of samples studied were peripheral
blood, and 35% were bone marrow. Peripheral blood samples
contained 54-99% blasts (median, 90%) and bone marrow
samples contained 80-100% blasts (median, 90%).
Surface antigen phenotype ofnormal CFU-GM. The mono-
clonal antibody panel was selected to provide maximum ability
to discriminate among different stages of granulocyte-monocyte
precursor cells ranging from the normal "mixed" colony
forming cell to the mature monocyte and granulocyte. The
reactivities of anti-Ia (anti-12), MY9, PM-8 1, AML-2-23, Mol,
Mo2, and MY3 with normal mature and immature bone
marrow myeloid cells determined primarily by cell sorting
experiments have previously been reported (8-13) and are
summarized in Fig. 1. To precisely compare the surface
antigens of L-CFC with corresponding normal progenitor cells,
the reactivity of this panel of antibodies with normal bone
marrow CFU-GM and CFU-Mix from a series of normal
donors was determined by complement lysis in experiments
performed simultaneously with L-CFC lysis experiments
(Table II).
As shown in Table II, CFU-Mix cells express Ia and MY9
antigens, but lack PM-81, AML-2-23, Mol, Mo2, and MY3.
The day 14 CFU-GM express Ia and MY9, and in addition
SURFACE ANTIGENS OF NORMAL
BONE MARROW MYELOID CELLS
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Figure 1. Schematic representation of the distribution of surface
antigens on normal bone marrow myeloid cells.
express PM-8 1 (on 59% of cells). The most mature clonogenic
cell, the day 7 CFU-GM, expresses Ia, MY9, and PM-8 1, and
now also expresses AML-2-23 antigen. As shown in Table II,
the acquisition of these differentiation-associated antigens during
normal hematopoiesis may be "gradual," particularly in the
cases of PM-81 and AML-2-23 antigens as summarized sche-
matically in Fig. 1. Further, the data indicate that the antigens
Ia, MY9, PM-81, AML-2-23, Mol, Mo2, and MY3 are added
sequentially during normal monocyte development from CFU-
Mix cells, and thus can be used to phenotypically "order"
different stages of hematopoietic cells; i.e., a cell expressing Ia,
MY9, and PM-81 is more mature than a cell expressing only
Ia and MY9.
Surface antigen phenotype ofL-CFC. A comparison of the
surface antigens expressed by the total AML cell population
(determined by indirect immunofluorescence) and the L-CFC
(determined by complement lysis) is shown in Table III. The
plating efficiency of the leukemic samples ranged from 44±8
to 2,992±80 colonies per 105 cells. In those cases where
preliminary studies revealed colony overgrowth at 5 X 104
cells/culture, cells were plated at 1.25 X 104 cells/culture. The
relationship of the number of colonies obtained to number of
cells plated was determined by plating leukemic cells from
cases 5, 8, 9, and 16 at concentrations from 1.5 X 103 to 5
X 104 cells per culture. Fig. 2 shows a linear relationship
between the number of cells plated and the number of colonies
observed within this range.
90% of the samples tested expressed Ia, MY9, and PM-8 1
on >20% of the total cell population, while AML-2-23 was
positive on 84%, Mol on 85%, Mo2 on 37%, and MY3 on
40%. As described, different surface antigen phenotypes correlate
with certain morphologic features (21). FAB Ml and M2
leukemias tend to express antigens of early myeloid cells such
as MY9, and lack antigens of later monocytoid cells such as
MY3 and Mo2, while myelomonocytic leukemias (FAB M4)
tend to express the monocyte markers MY3 and Mo2. In the
present series, eight of nine cases that expressed Mo2, MY3,
or both were thus classified as AMML (FAB M4), and only
one of six cases of Ml or M2 leukemia expressed either of
these two monocyte antigens on >20% of leukemic cells. It is
noteworthy that both of the M5 cases (classified independently
by morphology and cytochemistry) lacked expression of Mo2
and MY3, an uncommon finding in monocytic leukemia. Of
the three Ml leukemia cases evaluated for expression of all
the antigens, all three expressed la, MY9, and Mo I (low
antigen density of Mo 1 in each case), two expressed PM-8 1,
and no cases expressed AML-2-23, Mo2, or MY3.
The phenotypes of the L-CFC were frequently different
from the phenotypes of the majority cell populations (Table
III). Ia antigen was expressed on 42-100% of L-CFC (median
90%), MY9 on 21-99% (median 91%), PM-8 1 on 0-96%
(median 66%), AML-2-23 on 0-96% (median 20%), Mol on
3 0-61% (median 2%), Mo2 on 0-34% (median 0%), and MY3
on 0-32% (median 6%). A two-sided sign test (22) was used
to determine if there were any significant differences between
the percentages of total cells expressing each antigen, and the
percentage of L-CFC expressing that antigen. Ia and MY9
were expressed on a higher percentage of L-CFC than total
cells (P = 0.02 and 0.001, respectively), while Mo1 and Mo2
were expressed on a higher percentage of total cells than
748 Sabbath, Ball, Larcom, Davis, and Griffin
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Table II. Surface Antigens ofNormal Bone Marrow Colony Forming Cells
Percent
Antigen cells* positive Percent positive coloniest
Day 7 P§ Day 14 P CFU- Mix P
CFU-GM CFU-GM
Ia 21±4 87±111 NS 95±8 NS 91±121 0.006
MY9 40±13 85+14 NS 59±1915 0.03 65±16J} 0.006
PM-81 29±8 71±19 - 0.016 5±90.03 7± } NS
AML-2-23 56±27 54±24 29±15 10±18
Mol 38±7 10±9 12±10 0
Mo2 11±3 9±9 8±9 0
MY3 12±2 11±2 9±8 0
* Percent of total bone marrow mononuclear cells positive by indirect immunofluorescence (10,000 cells analyzed, three samples, mean±SD).
f Percent decrease in colonies after treatment with antibody and complement, compared to treatment with negative control antibody and com-
plement, mean+SD of six experiments with triplicate cultures in each.
§ P values based on one-sided sign test. NS, not significant.
L-CFC (P = 0.01 and 0.02, respectively). Most importantly, detected on L-CFC. In cases where clusters were found in
in virtually every case there were one or more "late" antigens addition to colonies, the phenotype of clusters was similar to
expressed on the majority of leukemic cells that were not the phenotype of colonies (data not shown). Two antigens, Ia
Table III. Comparison ofSdarce Antigens of the Total AML Cell Population and the L-CFC
Percent antigen positive cells
IA MY9 PM-81 AML-2-23 Mol Mo2 MY3
Patient L-CFC/105
number cells* Totalt L-CFC§ Total L-CFC Total L-CFC Total L-CFC Total L-CFC Total L-CFC Total L-CFC
1 768±176 79 (95) 5 (31) 45 (18) 71 (29) 34 (0) 7 (0) 24 (0)
2 536±56 97 (100) 72 (96) NA (10) NA (5) 3 (21) 1 (15) 1 (6)
3 110±8 54 (100) 74 (91) 35 (0) 49 (0) 54 (28) NA (NA) 46 (15)
4 169±9 93 (93) 86 (99) 64 (25) 13 (20) 42 (0) 10 (0) 10 (14)
5 740±66 60 (99) 37 (98) 18 (24) 10 (6) 21 (0) 6 (0) 6 (11)
6 126±18 13 (42) 65 (79) 29 (0) 22 (0) 38 (0) 17 (0) 17 (23)
7 252±18 82 (62) 72 (78) 96 (20) 96 (0) 76 (0) 4 (0) 2 (0)
8 2,992±80 85 (84) 86 (99) 92 (93) 64 (49) 22 (11) 9 (17) 6 (7)
9 2,208±196 97 (76) 53 (78) 92 (80) 75 (0) 41 (0) 2 (20) 7 (12)
10 256±46 31 (52) 60 (99) 65 (75) 15 (39) 17 (34) 16 (0) 13 (16j
11 922±6 65 (46) 97 (96) 89 (50) 69 (0) 80 (44) 43 (0) 66 (0)
12 1,200±92 4 (57) 98 (99) 74 (53) 52 (40) 39 (12) 9 (19) 6 (32)
13 64± 10 72 (94) 50 (69) 87 (56) 93 (0) 90 (0) 83 (34) 94 (0)
14 136±6 37 (71) 51 (80) 99 (96) 75 (12) 8 (0) 23 (0) 16 (11)
15 622±38 94 (99) 25 (84) 78 (85) 83 (59) 79 (4) 63 (12) 75 (11)
16 1,508±132 79 (98) 71 (99) 90 (98) 71 (81) 71 (7) 56 (0) 64 (0)
17 64±10 93 (94) 66 (91) 87 (84) 80 (75) 74 (0) 54 (5) 78 (6)
18 132±16 87 (94) 69 (92) 99 (96) 78 (96) 89 (61) 8 (0) 9 (0)
19 44±8 59 (68) 66 (100) 85 (77) 79 (55) 82 (22) 31 (0) 65 (0)
20 175±5 79 (87) 75 (21) 84 (93) 88 (91) 30 (0) 14 (0) 18 (0)
P value" 0.02 0.001 0.06 0.06 0.001 0.02 0.26
* L-CFC/105 cells (sham treated with control antibody and complement) (mean±SD of quadruplicate cultures).
tPercent of total AML cells positive by indirect immunofluorescence (10,000 cells analyzed).
§ Percent decrease in L-CFC number following L-CFC lysis by antibody and complement (mean of quadruplicate cultures, data shown is one of
two representative experiments).
IIP values based on a two-sided sign test comparing "total" versus "L-CFC" for each antigen.
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Figure 2. Effects of leukemic cell concentration on L-CFC cloning
efficiency. Cells from four cases (A, B, C, and D represent cases 8,
16, 9, and 5, respectively) were cultured in agar at cell concentrations
from 1.5 X 103 cells/ml culture to 50 X 10! cells/culture, and L-CFC
enumerated on day 7.
and MY9, were detected on the majority of L-CFC from
almost all cases studied. PM-81 and.AML-2-23 antigens svvre
expressed on the L-CFC from some cas s, but not from others
(despite being expressed on the majority of leukemic cells
from 94 and 84% of cases, respectively). Further, although
several cases were identified in which L-CFC were PM-881
positive and AML-2-23 negative, the converse was not observed.
The data in Table III thus suggest that several "stages" of
L-CFC could be distinguished by surface antigen phenotype:
a stage at which only Ia and MY9 were expressed, a stage at
which PM-8 1 antigen was acquired in addition to Ia and MY9,
andq a stage at which AML-2-23 was acquired in addition to
Ia, MY9, and PM-8 1. In an effort to investigate these apparent
stages in more detail, groups of patients with similar L-CFC
phenotypes were identified (arbitrarily defining an antigen as
"positive" if there was 50-100% lysis of L-CFC, and "negati'e"
if there was 0-49% lysis). It should be noted that the majority
of positive results had greater than 75% lysis, and the majority
of negative results less than 25%. Using this definition, the
L-CFC of the 20 cases analyzed here (Table III) were divided
into three phenotypic groups. Patients 2, 3, 4, 5, and 7 (group
I) expressed Ia and MY9 on L-CFC, but lacked PM-8 1, AML-
2-23, Mo 1, Mo2, and MY3. Two additional patients were
included in this group. Patient 1 expressed Ia on 95% on L-
CFC but MY9 was low (31%). Patient 6 expressed MY9 on
79% but Ia expression was low (42%). However, PM-8 1, AML-
2-23, Mo 1, Mo2, and MY3 were not detected on the L-CFC
of either case. Cases 8-14 (group II) expressed la, MY9, and
PM-81 on L-CFC, but lacked AML-2-23, Mol, Mo2, and
MY3. One additional patient was included in this group.
Patient I I expressed MY9 on 96% of L-CFC, and PM-81 on
50% but Ia was low (46%). Patients 15-19 (group III) expressed
Ia, MY9, PM-8 1, and,AML-2-23 on L-CFC. One additional
patient (20) expressed Ia on 87%, PM-81 on 93%, AML-2-23
on 91% of L-CFC, but MY9 was low (21%).
The three arbitrarily-defined L-CFC groups were further
analyzed to determine if there were any biologically or clinically
significant correlations between L-CFC phenotype, surface
antigens expressed by the total cell population, and FAB
classification (Table IV). Within each group, the leukemic cell
populations have acquired surface antigens that are not ex-
pressed on the L-CFC as noted above. For example, a majority
of cells in the total cell population of cases in group I expressed
PM-81, AML-2-23, and Mol in addition to la and MY9
antigens present onithe L-CFC. Group II patients tend to
acquire AML-2-23, Mol, and Mo2 on the total cell population,
while group III patients expressed Mol in 100% of the cases,
Mo2. in 67%, and MY3 in 67%. The FAB subsets were
disproportionately distributed among the L-CFC groups, with
all of the Ml patients in group I, and 91% of the M4 patients
in groups II and III. These results suggest that the surface
antigens and thus the level of differentiation attained by the
majority leukemic cell population (21) in many cases ofAML
are at least partially related to the stage of differentiation of
the L-CFC.
These results also make it possible to relate the L-CFC to
a counterpart normal myeloid cell. The relationship between
the phenotypes of L-CFC and normal myeloid progenitor cells
is illustrated schematically in Fig. 3.
Table IV Phenotypic Groups ofL-CFC
Distribution of cases by FAB
Percent of cases expressing antigen on greater than 20% of total cell population classification
L-CFC* group la M'9 PM-81 AML-2-23 Mol Mo2 MY3 Ml M2 M4 M5
n % % %
I (Ia+, MY9+) 7 86 86 83 50 86 0 29 4 1 1 1
II (Ia+, MY9+,
PM-8 1+) 7 86 100 100 86 71 43 29 0 0 6 1
III (Ia+, MY9+, PM-
81+, AML-2-23+) 6 100 100 100 100 100 67 67 0 1 4 0
P valuef 1.0t 1.0 0.63 0.15 0.48 0.07 0.33 0.013§
* L-CFC groups are identified by surface antigen phenotype of the L-CFC (each antigen expressed on 50-100% of L-CFC in each case).
f P values based on Fisher's Exact Test (22) to determine if the probability of expression of each antigen is independent of the L-CFC group.
6 P value based on Fisher's Exhct Test for a 4 X 3 table = 0.013.
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Figure 3. Comparison of surface antigen phenotypes of L-CFC and
normal bone marrow progenitor cells. The surface antigens expressed
by the colony forming cells are shown (dotted pattern) along with the
surface antigens acquired during the process of differentiation of the
leukemic or normal progenitor cells (striped pattern).
Discussion
In this study, we have explored the relationships between
clonogenic AML cells and the total leukemic cell population
in detail using surface antigen analysis. The results show that
L-CFC are a distinct subpopulation of cells in all morphologic
types of AML and that the majority of cells in each patient
with AML are more differentiated than are the L-CFC of the
same patient. In order to ftirther investigate L-CFC heteroge-
neity, we defined three stages of L-CFC by differentiation
associated phenotypes. L-CFC from 7 of 20 cases studied
expressed only Ia and MY9; a second group of seven cases
expressed Ia, MY9, and PM-8 1, and a third group of six cases
expressed Ia, MY9, PM-81, and AML-2-23 (Table III). Inter-
estingly, these antigens are acquired in normal granulocyte-
monocytic differentiation in the same sequence (Fig. 1 and
Table II). Thus, L-CFC from one-third of the cases studied
here expressed surface antigens characteristic of multipotent
progenitor cells, one-third expressed antigens of an "early"
CFU-GM, and one-third expressed antigens of a "late" CFU-
GM. The correlations between L-CFC and normal granulocytic-
nionocytic progenitor cells demonstrate that AML is a heter-
ogeneous disorder not only at the level of the major population
of "terminal" leukemic cells (21), but also at the level of the
leukemic clonogenic cell, in agreement with the results of
Lange et al. (23) and our previous studies in acute myelomon-
ocytic leukemia (7).
Previous attempts to define the cell of origin ofAML have
also suggested that the leukemic stem cells may be derived
from very early progenitor cells. Fialkow (1) determined the
tlonality of AML cells by glucose-6-phosphate dehydrogenase
(G6PD) isoenzymes in four patients. In two pediatric cases,
erythroid cells were not found to be part of the malignant
clone, while in two adult cases, the disease appeared to involve
stem cells multipotent for myeloid cells, erythrocytes, and
platelets. Other groups have attempted to trace the AML clone
using marker chromosomes. Blackstock (24) et al. and Jensen
et al. (25) reported the presence of a marker chromosome in
erythroid lineage cells in cases of AML, and Reid et al. (26)
reported that a marker translocation t (lq-; 1llq+) could be
found in normal appearing CFU-GM from a child with AML,
suggesting that an early stem might be involved in the patho-
genesis of some cases of AML. The results presented here
support the observation of Fialkow (1) that some cases of
AML may originate in a multipotent progenitor cell, while
others arise in a later cell already committed to the myeloid
lineage. The possibility exists, however, that pluripotent stem
cells are involved in the leukemic process in most cases of
AML, but fail to proliferate in the assay system used here or
are present in very small numbers. Several observations tend
to support the concept that the L-CFC assayed in this study
are representative of the major clonogenic cell that can be
cultured. First, L-CFC with the phenotype of a multipotent
cell were observed in a distinct subset of cases, demonstrating
that such cells can be identified with this culture system.
Second, the clonogenic cells in each case of AML tended to
be a relatively uniform subset. Multiple levels of L-CFC in the
same patient thus were generally not observed, even though
L-CFC were strikingly different in different patients. Finally,
the majority of leukemic colonies in individual cases tended
to be of uniform size -(generally 20-40 cells) and to follow
similar kinetics in culture, suggesting that the L-CFC are a
reasonably homogeneous population with respect to prolifer-
ative potential, unlike normal bone marrow progenitor cells.
However, it is not possible to be certain that any culture
system will promote gtowth of the earliest possible leukemic
progenitor cell, or that the in vitro clonogenic cells are repre-
sentative of in vivo stem cells. Similar studies need to be done
with the other L-CFC culture systems (3, 27, 28). It may be
possible to determn ine if the different assay systems detect the
same L-CFC cell by using the surface antigen phenotype
methods described here. Data from other laboratories suggest
that agar and methyl cellulose L-CFC culture systems may be
similar (15). In our own pilot studies comparing agar and
methylcellulose cultures, no reproducible differences in colony
number or size were observed. Agar was selected because of
the ease with which whole cultures could be stained cytochem-
ically for myeloid specific esterase activities. We chose to avoid
conditions that would support the growth of T cell colonies
(phytohemagglutinin or phytohemagglutinin-stimulated leu-
kocyte conditioned medium) (28). Every effort was also made
here to avoid "contamination" of leukemic cells with residual
normal CFU-GM by testing only patients with near total
replacement of marrow by leukemic cells, and by testing
peripheral blood when possible (where the number of possible
residual normal myeloid progenitor cells is several orders of
magnitude lower than the number of L-CFC).
The differentiation stage of the L-CFC did not correlate
with age in this study. Pediatric cases were equally distributed
amdng the groups of both multipotent and more differentiated
L-CFC, and the two oldest patients (patients 19 and 20) had
L-CFC in the most differentiated group (III). The AML
patients studied here, however, were de novo cases and did
not include patients with a prior history of a myelodysplastic
syndrome or a myeloproliferative disease. In these stem cell
disorders, the L-CPC tnight be anticipated to be more uniformly
related to a multipotent cell. However, it is also possible that
the final leukemic transforming event in these patients also
takes place in a later progenitor cell. It would be of interest to
determine self-renewal potential of the different stages of
L-CFC. Wouters et al. (6) have presented evidence that a
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hierarchy of AML blasts exists by demonstrating that cells
with high proliferative potential also have high self-renewal
capacity and can be distinguished from cells with lower prolif-
erative potential and lower self-renewal capacity.
There is ample evidence that AML cells and AML cell
lines can be induced to differentiate in vitro (8, 29-32). If the
L-CFC assayed in vitro do indeed function as leukemic stem
cells in vivo, then our results suggest that partial and often
abnormal degrees of differentiation are an on-going process in
vivo. It is interesting, however, that different stages of L-CFC
appear to have different abilities to differentiate, thus resulting
in different morphological and immunological phenotypes.
The most immature L-CFC (group I) tended to be associated
with FAB classification M l, while the more differentiated
L-CFC (groups II and III) tended to be associated with M4
and M5 (Table IV). The expression of surface antigens on the
total cell population was also related to the degree of differ-
entiation of the L-CFC. Thus, although Ia, MY9, and PM-81
antigens were expressed on the leukemic cells of all patients,
the percentage of cases expressing AML-2-23, Mo 1, Mo2, and
MY3, and the percentage of cells in each individual case
expressing these antigens, tended to increase from group I to
group II to group III. The analogies between leukemic and
normal differentiation are summarized in Fig. 3.
The results presented here have several implications for
the therapy of AML. The ability to immunologically purge
leukemic progenitor cells from a remission bone marrow could
allow autologous bone marrow transplantation despite the lack
of leukemia-specific markers. This approach has been used
successfully in the treatment of acute lymphoblastic leukemia
(anti-CALLA) (33) and aggressive histology lymphomas (anti-
Bl) (Nadler, L. M., T. Takvorian, L. Botnick, R. C. Bast, R.
Finberg, S. Hellman, G. P. Canellos, and S. F. Schlossman,
submitted for publication). The heterogeneity of AML cells,
especially at the level of the clonogenic cells, may make
application of this technique more difficult in AML. Our
results do demonstrate that antigens can be identified, such as
AML-2-23 and PM-8 1, that are not expressed on the multi-
potent normal progenitor cells needed for marrow recovery,
but are expressed on clonogenic cells from at least a subset of
AML patients. Anti-MY9 could also have clinical utility since
it reacts with only a fraction of normal multipotent progenitor
cells. Clinical trials with antibodies [AML-2-23 and PM-81
(34)] are underway, and may ultimately allow an assessment
of the biological significance of L-CFC.
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